FATE THERAPEUTICS
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI ... and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
FATE THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2007-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.fatetherapeutics.com
Total Employee:
101+
Status:
Closed
Contact:
8588751802
Email Addresses:
[email protected]
Total Funding:
1.21 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics WordPress Google Universal Analytics Sitelinks Search Box IPv6 Yoast WordPress SEO Plugin Google Maps
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-04-08 | Verio Therapeutics | Verio Therapeutics acquired by Fate Therapeutics | N/A |
Investors List
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Fate Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Fate Therapeutics
OVP Venture Partners
OVP Venture Partners investment in Series B - Fate Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Fate Therapeutics
Venrock
Venrock investment in Series B - Fate Therapeutics
Polaris Partners
Polaris Partners investment in Series B - Fate Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series B - Fate Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Fate Therapeutics
Venrock
Venrock investment in Series B - Fate Therapeutics
Sanofi Ventures
Sanofi Ventures investment in Series B - Fate Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-30 | Fate Therapeutics Appoints Brian T. Powl as Chief Commercial Officer |
| 2020-08-19 | Fate Therapeutics Taps Celgene’s Dulac as Its Chief Financial Officer |
Official Site Inspections
http://www.fatetherapeutics.com Semrush global rank: 2.24 M Semrush visits lastest month: 8.54 K
- Host name: mlchristyphoto.com
- IP address: 208.113.235.136
- Location: Brea United States
- Latitude: 33.9339
- Longitude: -117.8854
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 92821
More informations about "Fate Therapeutics"
Management - Fate Therapeutics
Fate’s management team has the passion and experience to explore new biology, develop innovative therapeutics, create formidable intellectual property, launch new business models and foster high-value strategic collaborations.See details»
Corporate Responsibility - Fate Therapeutics
Fate Therapeutics Announces Leadership Transition
Under his direction, the Company has established a world class R&D organization yielding numerous high-tier journal publications, over 500 issued patents, and a pipeline of highly …See details»
Corporate Governance - Fate Therapeutics, Inc.
The Board of Directors of Fate Therapeutics, Inc. sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound …See details»
Fate Therapeutics Inc. | LinkedIn
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …See details»
FATE THERAPEUTICS, INC.
Mar 1, 2023 incorporation or organization) (I.R.S. Employer. Identification No.) 12278 Scripps Summit Drive, San Diego, California 92131 (Address of principal executive offices) (Zip Code) …See details»
Fate Therapeutics, Inc. (FATE) Company Profile & Facts - Yahoo …
See the company profile for Fate Therapeutics, Inc. (FATE) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Fate Therapeutics - Crunchbase Company Profile
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San …See details»
Investors | Fate Therapeutics, Inc.
The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Fate Therapeutics, Inc. (FATE) - Yahoo Finance Canada
See the company profile for Fate Therapeutics, Inc. (FATE) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
About Us - Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders.See details»
Join Our Team - Fate Therapeutics
Join Fate Therapeutics and become a vital member of our team working to develop groundbreaking cellular immunotherapies for patients suffering from cancer and autoimmune …See details»
The Fate Way - Fate Therapeutics
The Fate Way was developed by employees and leaders, capturing the characteristics for how success is achieved through every step of the employee lifecycle! Our Mission We are …See details»
Fate Therapeutics Announces Leadership Transition - Yahoo Finance
Nov 29, 2024 Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC …See details»
Annual Reports and Proxies - Fate Therapeutics, Inc.
The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Fate Therapeutics - Overview, News & Similar companies - ZoomInfo
May 23, 2024 Fate Therapeutics contact info: Phone number: (858) 875-1800 Website: www.fatetherapeutics.com What does Fate Therapeutics do? Founded in 2007, Fate …See details»
Fate Therapeutics Announces Leadership Transition - Morningstar
Nov 29, 2024 Under his direction, the Company has established a world class R&D organization yielding numerous high-tier journal publications, over 500 issued patents, and a pipeline of …See details»
Fate Therapeutics Announces Leadership Transition - BioSpace
Dec 2, 2024 Under his direction, the Company has established a world class R&D organization yielding numerous high-tier journal publications, over 500 issued patents, and a pipeline of …See details»
Fate Therapeutics Reports Third Quarter 2024 Financial Results …
For more information, please visit www.fatetherapeutics.com. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities …See details»
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting …
Nov 9, 2024 Fate Therapeutics, Inc. Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies. Initial Low-Dose …See details»